½ÃÀ庸°í¼­
»óǰÄÚµå
1697156

¼¼°èÀÇ ¾È¸é ¸¶ºñ ½ÃÀå : ¾÷°è ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2025-2032³â)

Facial Palsy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Persistence Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 250 Pages | ¹è¼Û¾È³» : 2-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ¾È¸é ¸¶ºñ ½ÃÀå ±Ô¸ð´Â 2025³â¿¡ 25¾ï ´Þ·¯, 2032³â¿¡´Â 34¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. 2025³â-2032³âÀÇ ¿¹Ãø ±â°£¿¡ 4.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾È¸é ¸¶ºñ´Â ¾È¸é ±ÙÀ°¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ½Å°æ ÁúȯÀ¸·Î, Á¾Á¾ ½Å°æ ¼Õ»óÀ¸·Î ÀÎÇÑ ¾àÈ­¿Í ¸¶ºñ·Î À̾îÁý´Ï´Ù. ÀÌ ÁúȯÀº º§ ¸¶ºñ, ¿Ü»ó, ³úÁ¹Áß, Á¾¾ç ¶Ç´Â ¶óÀÓº´°ú °°Àº °¨¿°À¸·Î ÀÎÇØ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾È¸é ¸¶ºñ ½ÃÀå¿¡´Â ¾à¹° ¿ä¹ý, ¹°¸® ¿ä¹ý, ¼ö¼ú °³ÀÔ, °í±Þ ½Å°æ ÀÚ±Ø ÀåÄ¡ µîÀÇ Ä¡·á ¿É¼ÇÀÌ Æ÷ÇԵ˴ϴÙ. ¾È¸é ½Å°æ Àå¾ÖÀÇ ¹ßº´·ü Áõ°¡´Â Áø´Ü ¹× Ä¡·á ±â¼úÀÇ Áøº¸¿Í ÇÔ²² ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀ̵Ǿú½À´Ï´Ù. ÀÌ ½ÃÀåÀº º´¿ø, Àü¹® Ŭ¸®´Ð, ÀçȰ¼¾ÅÍ, ÀçÅà °£È£ ÇöÀå¿¡ ´ëÀÀÇϰí, ȯÀÚÀÇ °á°ú¸¦ °³¼±ÇÏ°í ¾È¸é ±â´ÉÀ» ȸº¹½Ã۱â À§ÇÑ ´Ù¾çÇÑ Ä¡·á¹ýÀ» Á¦°øÇÕ´Ï´Ù.

¼¼°èÀÇ ¾È¸é ¸¶ºñ ½ÃÀåÀº ½Å°æÁúȯÀÇ À¯º´·ü »ó½ÂÀ̳ª ³úÁ¹Áß°ú °ü·ÃµÈ ¾È¸é ¸¶ºñÀÇ ¿µÇâÀ» ¹Þ±â ½¬¿î °í·ÉÈ­ Àα¸ Áõ°¡ µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù. Á¶±â Áø´Ü°ú Ä¡·á¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡¿Í ½Å°æÀ̽Ä, ¾È¸é ÀçȰ¼ºÈ­ ¼ö¼ú, »ýüÀüÀÚÀÇÇÐ µîÀÇ ±â¼úÀû Áøº¸°¡ ÇÔ²² ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º¸Åø¸®´®Åö½Å(º¸Å彺) ÁÖ»ç ¹× Àç»ý ÀÇ·á Á¢±Ù¹ý°ú °°Àº Çõ½ÅÀûÀÎ Ä¡·á¹ýÀ» »ç¿ëÇÒ ¼ö ÀÖ°Ô µÊÀ¸·Î½á Ä¡·á È¿°ú¿Í ȯÀÚ ¸¸Á·µµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á, ¾ð¾î ¿ä¹ý ¹× ¹°¸® ¿ä¹ýÀ» Æ÷ÇÔÇÑ ÀçȰ ÇÁ·Î±×·¥¿¡ ´ëÇÑ °ü½É Áõ°¡´Â ½ÃÀå ¼ö¿ä¸¦ ´õ¿í ¹Ð¾î ¿Ã¸®°í ÀÖ½À´Ï´Ù.

À¯¸ÁÇÑ ¼ºÀå °¡´É¼ºÀÌ ÀÖÀ½¿¡µµ ºÒ±¸Çϰí, ¾È¸é ¸¶ºñ ½ÃÀåÀº ¼ö¼úÀÇ °í°¡ÀÇ ºñ¿ë, ¼÷·ÃµÈ ÀÇ·á Àü¹®°¡ÀÇ Á¦ÇÑµÈ °¡¿ë¼º, ƯÁ¤ Áö¿ªÀÇ ºÒÃæºÐÇÑ »óȯ Á¤Ã¥°ú °ü·ÃµÈ ¹®Á¦¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ »õ·Î¿î Ä¡·á¹ý°ú ÀÇ·á±â±â¿Í °ü·ÃµÈ ±ÔÁ¦ ¹®Á¦´Â ½ÃÀå ¼ºÀåÀ» ¹æÇØÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾È¸é º¯Çü°ú °ü·ÃµÈ »çȸÀû ³«Àΰú ½É¸®Àû °íÅëÀº Áø´Ü°ú Ä¡·á Áö¿¬À¸·Î À̾îÁ® ȯÀÚ °á°ú¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °úÁ¦¸¦ ÇØ°áÇϱâ À§Çؼ­´Â ÀÇ·áÅõÀÚÀÇ È®´ë, Á¤Ã¥°³Çõ, ȯÀÚ±³À°¿¡ ´ëÇÑ ³ë·ÂÀÌ ÇÊ¿äÇϸç, ¾È¸é½Å°æ¸¶ºñ Ä¡·á¿¡ÀÇ Á¢±Ù¼º°ú Àú·ÅÇÑ °¡°ÝÀ» Çâ»ó½Ãų Çʿ䰡 ÀÖ½À´Ï´Ù.

¾È¸é ¸¶ºñ ½ÃÀåÀº ½Å°æ ÀÚ±Ø ±â¼ú, Àç»ý ¿ä¹ý ¹× ³·Àº ħ½À ¼ö¼ú ±â¼úÀÇ ¹ßÀüÀ¸·Î Å« ¼ºÀå ±âȸ¸¦ °¡Á®¿É´Ï´Ù. Áٱ⼼Æ÷ Ä¡·á¿Í À¯ÀüÀÚ Ä¡·áÀÇ °³¹ßÀº ½Å°æ Àç»ý°ú ±â´É ȸº¹¿¡ ÀÖ¾î Çì¾Æ¸± ¼ö ¾ø´Â °¡´É¼ºÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿ø°Ý ÀÇ·á ¹× µðÁöÅÐ °Ç°­ ¼Ö·ç¼ÇÀÇ µµÀÔÀÌ ÁøÇàµÊ¿¡ µû¶ó ¿ø°ÝÁö¿¡¼­ÀÇ ÁøÂûÀÌ ¿ëÀÌÇØÁö°í, ÃæºÐÇÑ Ä¡·á¸¦ ¹ÞÀ» ¼ö ¾ø´Â Áö¿ªÀÇ È¯ÀÚ°¡ Àü¹®°¡¿¡ ÀÇÇÑ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖ°Ô µË´Ï´Ù. ¿¬±¸±â°ü, ÀÇ·á Á¦°øÀÚ, ÀÇ·á±â±â Á¦Á¶¾÷üÀÇ Çù¾÷Àº Çõ½ÅÀ» °¡¼ÓÈ­ÇÏ°í ½ÃÀå È®´ë¸¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ Áø´Ü µµ±¸¿Í ÀçȰ ÇÁ·Î±×·¥¿¡ ´ëÇÑ ÅõÀڴ ȯÀÚ °ü¸® ¹× Ä¡·á ¼º°ú °³¼±¿¡ ´õ¿í ±â¿©ÇÕ´Ï´Ù.

º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ ¾È¸é½Å°æ¸¶ºñ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, Áø´Üº°, Ä¡·áº°, ÃÖÁ¾¿ëµµº°, Áö¿ªº° µ¿Çâ ¹× ½ÃÀå ÁøÃâ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

  • ½ÃÀåÀÇ ¹üÀ§¿Í Á¤ÀÇ
  • ½ÃÀå ¿ªÇÐ
  • °Å½Ã°æÁ¦ ¿äÀÎ
  • COVID-19ÀÇ ¿µÇ⠺м®
  • ¿¹Ãø ¿äÀÎ- °ü·Ã¼º°ú ¿µÇâ

Á¦3Àå ºÎ°¡°¡Ä¡°¡ ÀÖ´Â ÅëÂû

Á¦4Àå °¡°Ý µ¿Ç⠺м®, 2019³â-2032³â

Á¦5Àå ¼¼°èÀÇ ¾È¸é ¸¶ºñ ½ÃÀå Àü¸Á

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • ½ÃÀå ±Ô¸ðÀÇ ºÐ¼®°ú ¿¹Ãø
    • °ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, 2019³â-2024³â
    • ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, 2025³â-2032³â
  • ¼¼°èÀÇ ¾È¸é ¸¶ºñ ½ÃÀå Àü¸Á : Áø´Üº°
    • ¼Ò°³, ÁÖ¿ä Á¶»ç °á°ú
    • °ú°Å ½ÃÀå ±Ô¸ð¿Í ¼ö·® ºÐ¼®, Áø´Üº°, 2019³â-2024³â
    • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·® ºÐ¼®°ú ¿¹Ãø, Áø´Üº°, 2025³â-2032³â
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Áø´Üº°
  • ¼¼°èÀÇ ¾È¸é ¸¶ºñ ½ÃÀå Àü¸Á: Ä¡·áº°
    • ¼Ò°³, ÁÖ¿ä Á¶»ç °á°ú
    • °ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, Ä¡·áº°, 2019³â-2024³â
    • ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, Ä¡·áº°, 2025³â-2032³â
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Ä¡·á
  • ¼¼°èÀÇ ¾È¸é ¸¶ºñ ½ÃÀå Àü¸Á: ÃÖÁ¾ ¿ëµµº°
    • ¼Ò°³, ÁÖ¿ä Á¶»ç °á°ú
    • °ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, ÃÖÁ¾ ¿ëµµº°, 2019³â-2024³â
    • ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, ÃÖÁ¾ ¿ëµµº°, 2025³â-2032³â
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ÃÖÁ¾ ¿ëµµº°

Á¦6Àå ¼¼°èÀÇ ¾È¸é ¸¶ºñ ½ÃÀå Àü¸Á: Áö¿ªº°

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • °ú°Å ½ÃÀå ±Ô¸ð¿Í ¼ö·®(´ÜÀ§) ºÐ¼®, Áö¿ªº°, 2019³â-2024³â
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·®(´ÜÀ§) ºÐ¼®°ú ¿¹Ãø, Áö¿ªº°, 2025³â-2032³â
    • ºÏ¹Ì
    • À¯·´
    • µ¿¾Æ½Ã¾Æ
    • ³²¾Æ½Ã¾Æ¿Í ¿À¼¼¾Æ´Ï¾Æ
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Áö¿ªº°

Á¦7Àå ºÏ¹ÌÀÇ ¾È¸é ¸¶ºñ ½ÃÀå Àü¸Á

Á¦8Àå À¯·´ÀÇ ¾È¸é ¸¶ºñ ½ÃÀå Àü¸Á

Á¦9Àå µ¿¾Æ½Ã¾Æ ¾È¸é ¸¶ºñ ½ÃÀå Àü¸Á

Á¦10Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ ¾È¸é¸¶ºñ½ÃÀå Àü¸Á

Á¦11Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ ¾È¸é ¸¶ºñ ½ÃÀå Àü¸Á

Á¦12Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¾È¸é ¸¶ºñ ½ÃÀå Àü¸Á

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2025³â
  • ½ÃÀå ±¸Á¶
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ(»ó¼¼ - °³¿ä, À繫, Àü·«, ÃÖ±Ù µ¿Çâ)
    • Pfizer Inc.
    • Sanofi
    • Brainlab AG
    • GE Healthcare
    • GlaxoSmithKline plc
    • iTENS Australia
    • Johnson &Johnson Services, Inc.
    • MED-EL Medical Electronics
    • Medtronic plc
    • Natus Medical
    • Nihon Kohden Corporation
    • Novartis AG
    • Siemens Healthineers AG
    • TensCare Ltd.
    • Teva Pharmaceutical Industries Ltd.

Á¦14Àå ºÎ·Ï

SHW 25.04.15

Persistence Market Research has recently released a comprehensive report on the worldwide market for facial palsy. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global facial palsy market from 2025 to 2032.

Key Insights:

  • Facial Palsy Market Size (2025E): US$ 2.50 Bn
  • Projected Market Value (2032F): US$ 3.41 Bn
  • Global Market Growth Rate (CAGR 2025 to 2032): 4.5%

Facial Palsy Market - Report Scope

Facial palsy is a neurological disorder that affects the facial muscles, leading to weakness or paralysis, often caused by nerve damage. The condition can result from Bell's palsy, trauma, stroke, tumors, or infections such as Lyme disease. The facial palsy market encompasses treatment options, including medications, physical therapy, surgical interventions, and advanced neurostimulation devices. The increasing incidence of facial nerve disorders, coupled with advancements in diagnostic and therapeutic technologies, is driving market growth. The market caters to hospitals, specialty clinics, rehabilitation centers, and homecare settings, offering a range of treatment modalities to improve patient outcomes and restore facial function.

Market Growth Drivers

The global facial palsy market is propelled by several key factors, including the rising prevalence of neurological disorders and the growing aging population, which is more susceptible to stroke-related facial paralysis. Increasing awareness about early diagnosis and treatment, coupled with technological advancements such as nerve grafting, facial reanimation surgery, and bioelectronic medicine, contributes to market expansion. Additionally, the availability of innovative therapies, including botulinum toxin injections and regenerative medicine approaches, enhances treatment efficacy and patient satisfaction. The growing focus on personalized medicine and rehabilitation programs, including speech and physiotherapy, further drives market demand.

Market Restraints

Despite promising growth prospects, the facial palsy market faces challenges related to the high cost of surgical procedures, limited availability of skilled healthcare professionals, and inadequate reimbursement policies in certain regions. Regulatory challenges associated with novel therapies and medical devices also hinder market growth. Furthermore, social stigma and psychological distress associated with facial deformities may lead to delayed diagnosis and treatment, affecting patient outcomes. Addressing these challenges requires increased healthcare investment, policy reforms, and patient education initiatives to enhance accessibility and affordability of facial palsy treatments.

Market Opportunities

The facial palsy market presents significant growth opportunities driven by advancements in neurostimulation technologies, regenerative therapies, and minimally invasive surgical techniques. The development of stem cell therapy and gene therapy holds immense potential in nerve regeneration and functional recovery. Additionally, the increasing adoption of telemedicine and digital health solutions facilitates remote consultation, improving access to expert care for patients in underserved regions. Collaborations between research institutions, healthcare providers, and medical device manufacturers can accelerate innovation and drive market expansion. Investments in AI-driven diagnostic tools and rehabilitation programs further contribute to improved patient management and treatment outcomes.

Key Questions Answered in the Report

  • What are the primary factors driving the growth of the facial palsy market globally?
  • Which treatment modalities and technologies are gaining traction in the facial palsy landscape?
  • How are technological advancements reshaping the competitive landscape of the facial palsy market?
  • Who are the key players contributing to the facial palsy market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global facial palsy market?

Competitive Intelligence and Business Strategy

Leading players in the global facial palsy market, including Medtronic Plc, Stryker Corporation, Boston Scientific Corporation, and Abbott Laboratories, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced neurostimulation devices, regenerative therapies, and minimally invasive surgical solutions. Collaborations with healthcare providers, research institutions, and regulatory agencies facilitate market access and promote technology adoption. Moreover, emphasis on clinical research, evidence-based practice, and patient education fosters market growth and enhances patient outcomes in the evolving facial palsy treatment landscape.

Key Companies Profiled:

  • Medtronic Plc
  • Stryker Corporation
  • Boston Scientific Corporation
  • Abbott Laboratories
  • Ipsen S.A.
  • Revance Therapeutics Inc.
  • Checkpoint Surgical Inc.
  • Astellas Pharma Inc.
  • Medline Industries Inc.
  • BTL Industries Inc.

Facial Palsy Market Segmentation

By Diagnosis

  • Electromyography (EMG)
  • CT
  • MRI

By Treatment

  • Surgical
  • Non-Surgical

By End Use

  • Hospitals
  • Specialty Clinics

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Middle East and Africa
  • Latin America

Table of Contents

1. Executive Summary

  • 1.1. Global Facial Palsy Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Diagnosis Adoption Analysis
  • 3.2. Regulatory Landscape
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Price Trend Analysis, 2019-2032

  • 4.1. Key Highlights
  • 4.2. Key Factors Impacting Diagnosis Prices
  • 4.3. Pricing Analysis By Diagnosis
  • 4.4. Regional Prices and Diagnosis Preferences

5. Global Facial Palsy Market Outlook:

  • 5.1. Key Highlights
    • 5.1.1. Market Volume (Units) Projections
    • 5.1.2. Market Size (US$ Bn) and Y-o-Y Growth
    • 5.1.3. Absolute $ Opportunity
  • 5.2. Market Size (US$ Bn) Analysis and Forecast
    • 5.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 5.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 5.3. Global Facial Palsy Market Outlook: Diagnosis
    • 5.3.1. Introduction / Key Findings
    • 5.3.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Diagnosis, 2019-2024
    • 5.3.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Diagnosis, 2025-2032
      • 5.3.3.1. Electromyography (EMG)
      • 5.3.3.2. CT
      • 5.3.3.3. MRI
  • 5.4. Market Attractiveness Analysis: Diagnosis
  • 5.5. Global Facial Palsy Market Outlook: Treatment
    • 5.5.1. Introduction / Key Findings
    • 5.5.2. Historical Market Size (US$ Bn) Analysis, By Treatment, 2019-2024
    • 5.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2025-2032
      • 5.5.3.1. Surgical
      • 5.5.3.2. Non-Surgical
  • 5.6. Market Attractiveness Analysis: Treatment
  • 5.7. Global Facial Palsy Market Outlook: End Use
    • 5.7.1. Introduction / Key Findings
    • 5.7.2. Historical Market Size (US$ Bn) Analysis, By End Use, 2019-2024
    • 5.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
      • 5.7.3.1. Hospitals
      • 5.7.3.2. Specialty Clinics
  • 5.8. Market Attractiveness Analysis: End Use

6. Global Facial Palsy Market Outlook: Region

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Region, 2019-2024
  • 6.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Region, 2025-2032
    • 6.3.1. North America
    • 6.3.2. Europe
    • 6.3.3. East Asia
    • 6.3.4. South Asia and Oceania
    • 6.3.5. Latin America
    • 6.3.6. Middle East & Africa
  • 6.4. Market Attractiveness Analysis: Region

7. North America Facial Palsy Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Diagnosis
    • 7.2.3. By Treatment
    • 7.2.4. By End Use
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. U.S.
    • 7.3.2. Canada
  • 7.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Diagnosis, 2025-2032
    • 7.4.1. Electromyography (EMG)
    • 7.4.2. CT
    • 7.4.3. MRI
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2025-2032
    • 7.5.1. Surgical
    • 7.5.2. Non-Surgical
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
    • 7.6.1. Hospitals
    • 7.6.2. Specialty Clinics
  • 7.7. Market Attractiveness Analysis

8. Europe Facial Palsy Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Diagnosis
    • 8.2.3. By Treatment
    • 8.2.4. By End Use
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. Germany
    • 8.3.2. France
    • 8.3.3. U.K.
    • 8.3.4. Italy
    • 8.3.5. Spain
    • 8.3.6. Russia
    • 8.3.7. Turkey
    • 8.3.8. Rest of Europe
  • 8.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Diagnosis, 2025-2032
    • 8.4.1. Electromyography (EMG)
    • 8.4.2. CT
    • 8.4.3. MRI
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2025-2032
    • 8.5.1. Surgical
    • 8.5.2. Non-Surgical
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
    • 8.6.1. Hospitals
    • 8.6.2. Specialty Clinics
  • 8.7. Market Attractiveness Analysis

9. East Asia Facial Palsy Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Diagnosis
    • 9.2.3. By Treatment
    • 9.2.4. By End Use
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. South Korea
  • 9.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Diagnosis, 2025-2032
    • 9.4.1. Electromyography (EMG)
    • 9.4.2. CT
    • 9.4.3. MRI
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2025-2032
    • 9.5.1. Surgical
    • 9.5.2. Non-Surgical
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
    • 9.6.1. Hospitals
    • 9.6.2. Specialty Clinics
  • 9.7. Market Attractiveness Analysis

10. South Asia & Oceania Facial Palsy Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Diagnosis
    • 10.2.3. By Treatment
    • 10.2.4. By End Use
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. India
    • 10.3.2. Southeast Asia
    • 10.3.3. ANZ
    • 10.3.4. Rest of South Asia & Oceania
  • 10.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Diagnosis, 2025-2032
    • 10.4.1. Electromyography (EMG)
    • 10.4.2. CT
    • 10.4.3. MRI
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2025-2032
    • 10.5.1. Surgical
    • 10.5.2. Non-Surgical
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
    • 10.6.1. Hospitals
    • 10.6.2. Specialty Clinics
  • 10.7. Market Attractiveness Analysis

11. Latin America Facial Palsy Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Diagnosis
    • 11.2.3. By Treatment
    • 11.2.4. By End Use
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. Brazil
    • 11.3.2. Mexico
    • 11.3.3. Rest of Latin America
  • 11.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Diagnosis, 2025-2032
    • 11.4.1. Electromyography (EMG)
    • 11.4.2. CT
    • 11.4.3. MRI
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2025-2032
    • 11.5.1. Surgical
    • 11.5.2. Non-Surgical
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
    • 11.6.1. Hospitals
    • 11.6.2. Specialty Clinics
  • 11.7. Market Attractiveness Analysis

12. Middle East & Africa Facial Palsy Market Outlook:

  • 12.1. Key Highlights
  • 12.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019-2024
    • 12.2.1. By Country
    • 12.2.2. By Diagnosis
    • 12.2.3. By Treatment
    • 12.2.4. By End Use
  • 12.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 12.3.1. GCC Countries
    • 12.3.2. Egypt
    • 12.3.3. South Africa
    • 12.3.4. Northern Africa
    • 12.3.5. Rest of Middle East & Africa
  • 12.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Diagnosis, 2025-2032
    • 12.4.1. Electromyography (EMG)
    • 12.4.2. CT
    • 12.4.3. MRI
  • 12.5. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2025-2032
    • 12.5.1. Surgical
    • 12.5.2. Non-Surgical
  • 12.6. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
    • 12.6.1. Hospitals
    • 12.6.2. Specialty Clinics
  • 12.7. Market Attractiveness Analysis

13. Competition Landscape

  • 13.1. Market Share Analysis, 2025
  • 13.2. Market Structure
    • 13.2.1. Competition Intensity Mapping By Market
    • 13.2.2. Competition Dashboard
  • 13.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 13.3.1. Pfizer Inc.
      • 13.3.1.1. Overview
      • 13.3.1.2. Segments and Diagnosis Types
      • 13.3.1.3. Key Financials
      • 13.3.1.4. Market Developments
      • 13.3.1.5. Market Strategy
    • 13.3.2. Sanofi
    • 13.3.3. Brainlab AG
    • 13.3.4. GE Healthcare
    • 13.3.5. GlaxoSmithKline plc
    • 13.3.6. iTENS Australia
    • 13.3.7. Johnson & Johnson Services, Inc.
    • 13.3.8. MED-EL Medical Electronics
    • 13.3.9. Medtronic plc
    • 13.3.10. Natus Medical
    • 13.3.11. Nihon Kohden Corporation
    • 13.3.12. Novartis AG
    • 13.3.13. Siemens Healthineers AG
    • 13.3.14. TensCare Ltd.
    • 13.3.15. Teva Pharmaceutical Industries Ltd.

14. Appendix

  • 14.1. Research Methodology
  • 14.2. Research Assumptions
  • 14.3. Acronyms and Abbreviations
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦